Ximedica announces partnership with Moderna, Inc. (Nasdaq: MRNA) to develop a prototype for rapid mobile manufacturing of vaccines

Rhea-AI Summary

Ximedica has partnered with Moderna (Nasdaq: MRNA) to create a prototype for rapid mobile vaccine and therapeutic manufacturing under DARPA's Nucleic Acids On-Demand World-Wide Program. The collaboration, which spans four years, aims to develop a mobile platform that can quickly diagnose and respond to pathogen threats. Ximedica will receive up to $11 million in funding for this initiative. The project envisions manufacturing units that can produce hundreds of doses in just days, ensuring timely medical responses in remote locations worldwide.

Positive

• Partnership with Moderna may enhance MRNA's capabilities in rapid vaccine production.
• Potential to receive up to $11 million in funding boosts financial resources for the project.

Negative

• None.

PROVIDENCE, R.I., March 31, 2021 /PRNewswire/ -- Ximedica today announced a partnership with Moderna, Inc. (Nasdaq: MRNA) to develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the Defense Advanced Research Projects Agency's (DARPA) Nucleic Acids On-Demand World-Wide (NOW) Program. Integrating Moderna's proprietary mRNA technology with Ximedica's instrument design and engineering expertise, both teams will work closely together in an effort to meet capability expectations set out by the DARPA program over the 4-year partnership. As part of the agreement, Ximedica will receive up to $11 million in funding.

DARPA's Nucleic Acids On-Demand World-Wide initiative aims to develop a mobile, just-in-time manufacturing platform that quickly diagnoses pathogen threats and provides medical countermeasures to deliver pandemic prevention treatments in-field. The resulting Good Manufacturing Practice (GMP) quality mRNA vaccines and therapeutics are intended to deliver near-instantaneous protections to both military personnel and local populations. The design envisions a manufacturing unit capable of producing hundreds of doses of medicines in a matter of days in a 6-foot x 6-foot x 6-foot (1.8m x 1.8m x 1.8m) container in remote locations around the world.

"Ximedica is honored to partner with Moderna on this very important DARPA NOW project. Together, we will work towards creating an innovative, deployable, robust prototype solution that can respond quickly to future pathogen outbreaks at their source, anywhere on the planet." Fernando Oliveira, VP Strategic Development Diagnostics

About Ximedica
Ximedica designs and develops healthcare products through world class engineering to manufacturing. We stay flexible and accountable to create products that are innovative, easy to use, and commercially viable.

 

View original content:http://www.prnewswire.com/news-releases/ximedica-announces-partnership-with-moderna-inc-nasdaq-mrna-to-develop-a-prototype-for-rapid-mobile-manufacturing-of-vaccines-301260834.html

SOURCE Ximedica

FAQ

What is the new partnership between Moderna and Ximedica about?

Moderna and Ximedica are collaborating to develop a mobile manufacturing platform for vaccines and therapeutics as part of DARPA's initiative.

How much funding will Ximedica receive from the partnership with Moderna?

Ximedica will receive up to $11 million in funding for the partnership.

What is the goal of DARPA's Nucleic Acids On-Demand World-Wide Program?

The goal is to create a mobile platform that can quickly diagnose pathogen threats and deliver medical countermeasures.

How long will the partnership between Moderna and Ximedica last?

The partnership is set to last four years.

What are the expected capabilities of the mobile manufacturing unit?

The unit is designed to produce hundreds of doses of mRNA vaccines in a compact container within days.